Neogenomics Stock Performance
| NEO Stock | USD 9.49 0.35 3.56% |
The company secures a Beta (Market Risk) of 2.06, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NeoGenomics will likely underperform. At this point, NeoGenomics has a negative expected return of -0.74%. Please make sure to verify NeoGenomics' skewness, as well as the relationship between the day median price and relative strength index , to decide if NeoGenomics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days NeoGenomics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 0.15 | Five Day Return (9.56) | Year To Date Return (40.33) | Ten Year Return 107.59 | All Time Return 2.2 K |
Last Split Factor 1:100 | Last Split Date 2003-04-16 |
1 | Disposition of 7070 shares by Harris Melody of NeoGenomics subject to Rule 16b-3 | 12/31/2024 |
2 | NEO Battery Materials Unveils Breakthrough Silicon Battery Capacity, Expanding to Space Industry with Solid-State Batteries | 01/07/2025 |
3 | Acquisition by Williams Felicia of 5430 shares of NeoGenomics at 13.59 subject to Rule 16b-3 | 01/22/2025 |
4 | NEO Battery Materials to Establish Canadas First Silicon Anode Facility on 8 Acres in Windsor, Ontario | 01/24/2025 |
5 | Why NeoGenomics Shares Are Trading Lower Today | 02/18/2025 |
6 | Q4 2024 Neogenomics Inc Earnings Call Transcript | 02/19/2025 |
7 | NeoGenomics Given New 18.00 Price Target at Needham Company LLC | 02/20/2025 |
8 | Acquisition by Sherman Jeffrey Scott of 126476 shares of NeoGenomics subject to Rule 16b-3 | 02/21/2025 |
9 | Disposition of 2472 shares by Warren Stone of NeoGenomics subject to Rule 16b-3 | 02/25/2025 |
10 | NeoGenomics Given New 18.00 Price Target at Piper Sandler | 02/27/2025 |
11 | NeoGenomics Inc Shares Up 2.46 percent on Mar 6 | 03/06/2025 |
12 | Labcorp is Set to Acquire Select Assets of BioReference Health of OPK | 03/14/2025 |
| Begin Period Cash Flow | 342.5 M |
NeoGenomics |
NeoGenomics Relative Risk vs. Return Landscape
If you would invest 1,649 in NeoGenomics on December 18, 2024 and sell it today you would lose (695.50) from holding NeoGenomics or give up 42.18% of portfolio value over 90 days. NeoGenomics is generating negative expected returns assuming volatility of 5.8056% on return distribution over 90 days investment horizon. In other words, 51% of stocks are less volatile than NeoGenomics, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
NeoGenomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NeoGenomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NeoGenomics, and traders can use it to determine the average amount a NeoGenomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1272
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NEO |
Estimated Market Risk
| 5.81 actual daily | 51 51% of assets are less volatile |
Expected Return
| -0.74 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average NeoGenomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NeoGenomics by adding NeoGenomics to a well-diversified portfolio.
NeoGenomics Fundamentals Growth
NeoGenomics Stock prices reflect investors' perceptions of the future prospects and financial health of NeoGenomics, and NeoGenomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NeoGenomics Stock performance.
| Return On Equity | -0.0854 | ||||
| Return On Asset | -0.027 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 1.48 B | ||||
| Shares Outstanding | 128.46 M | ||||
| Price To Earning | 272.37 X | ||||
| Price To Book | 1.40 X | ||||
| Price To Sales | 1.91 X | ||||
| Revenue | 660.57 M | ||||
| Gross Profit | 290.1 M | ||||
| EBITDA | (1.51 M) | ||||
| Net Income | (78.73 M) | ||||
| Cash And Equivalents | 465.95 M | ||||
| Cash Per Share | 3.70 X | ||||
| Total Debt | 605.33 M | ||||
| Debt To Equity | 0.59 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 7.04 X | ||||
| Cash Flow From Operations | 7.02 M | ||||
| Earnings Per Share | (0.62) X | ||||
| Market Capitalization | 1.26 B | ||||
| Total Asset | 1.64 B | ||||
| Retained Earnings | (325.78 M) | ||||
| Working Capital | 294.78 M | ||||
| Current Asset | 82.36 M | ||||
| Current Liabilities | 40.06 M | ||||
About NeoGenomics Performance
By examining NeoGenomics' fundamental ratios, stakeholders can obtain critical insights into NeoGenomics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that NeoGenomics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 26.35 | 17.74 | |
| Return On Tangible Assets | (0.10) | (0.11) | |
| Return On Capital Employed | (0.07) | (0.07) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.09) | (0.08) |
Things to note about NeoGenomics performance evaluation
Checking the ongoing alerts about NeoGenomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NeoGenomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NeoGenomics generated a negative expected return over the last 90 days | |
| NeoGenomics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 660.57 M. Reported Net Loss for the year was (78.73 M) with profit before taxes, overhead, and interest of 290.1 M. | |
| NeoGenomics has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Labcorp is Set to Acquire Select Assets of BioReference Health of OPK |
- Analyzing NeoGenomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NeoGenomics' stock is overvalued or undervalued compared to its peers.
- Examining NeoGenomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NeoGenomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NeoGenomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NeoGenomics' stock. These opinions can provide insight into NeoGenomics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.62) | Revenue Per Share | Quarterly Revenue Growth 0.106 | Return On Assets |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.